Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recipharm Extends Partnership with Sato Pharmaceutical | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Recipharm Extends Partnership with Sato Pharmaceutical

The CDMO will manufacture Emla Patch for the Japanese market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Recipharm has entered into a long-term agreement with Sato Pharmaceutical Co. for the commercial manufacture and delivery of the Emla Patch to Japan. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato.

Recipharm’s facility in Karlskoga, Sweden will produce and deliver the product to Sato, which has headquarters in Tokyo. Recipharm says after a successful launch in Japan, it is expected that the annual volumes of Emla Patch to Sato will be a significant addition to the present production at the Karlskoga facility.

“We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further,” said Ingela Palmkvist, general manager at Recipharm in Karlskoga. “We are looking forward to the launch in Japan and cooperating with Sato in developing the business to the benefit of both companies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics